CD30 CAR-T in the Treatment of CD30 Positive Lymphoma

EARLY_PHASE1Not yet recruitingINTERVENTIONAL
Enrollment

15

Participants

Timeline

Start Date

July 28, 2025

Primary Completion Date

July 28, 2029

Study Completion Date

July 28, 2029

Conditions
LymphomaB Cell LymphomaCD30+ Peripheral T-cell Lymphoma
Interventions
DRUG

chimeric antigen receptor gene modified T cells

The rate of intravenous infusion of CD30 CAR T cells was 10 mL to 20 mL/min, and the infusion was performed using a blood transfusion apparatus with a filter screen. Use saline rinsing tube prior to infusion; Rinse the infusion bag with 10 mL\~30 mL normal saline.

Trial Locations (1)

Unknown

Tongji Hospital Affiliated to Tongji Medical College of HUST, Wuhan

All Listed Sponsors
collaborator

Tongji Hospital Affiliated to Tongji Medical College of HUST

UNKNOWN

collaborator

Shanxi Bethune Hospital

OTHER

collaborator

Wuhan Central Hospital

OTHER

collaborator

Yichang Central People's Hospital

OTHER

collaborator

First Affiliated Hospital of Guangxi Medical University

OTHER

lead

Shandong Qilu Cell Therapy Engineering Technology Co., Ltd

INDUSTRY